Thymulin (FTS / Zinc-Thymulin): A 2026 Research Guide

Thymulin (FTS / Zinc-Thymulin): A 2026 Research Guide
Educational use only. This article is informational and does not constitute medical advice. Peptide dosing decisions should be made in consultation with a licensed physician familiar with your medical history. Always verify any dose with your prescribing physician before drawing or administering. Some peptides discussed are not FDA-approved for human use; legal and regulatory status varies by jurisdiction.

Quick Answer

Thymulin (originally facteur thymique sérique, or FTS) is a 9-amino-acid peptide hormone secreted by thymic epithelial cells. Discovered by the Bach and Dardenne lab in Paris in the 1970s, it carries the longest mechanistic pedigree of any thymic peptide. Two facts dominate every honest discussion of it:

Table of Contents

  1. Thymulin is biologically inert without zinc. The apopeptide (the bare 9-amino-acid chain) does nothing in any reliable bioassay. Activity requires a 1:1 zinc-to-peptide complex. Dardenne and colleagues established this in a landmark 1982 PNAS paper (PMID 6957870). Vendor copy that ignores this is selling a chemistry it does not understand.
  2. Both blinded human trials were negative. The only randomized, double-blind, placebo-controlled human efficacy studies of thymulin (under the synthetic-analog name nonathymulin) were Amor 1987 in rheumatoid arthritis (PMID 3310925) and Roullet 1989 in multiple sclerosis (PMID 2618585). Neither produced significant clinical benefit over placebo. After Roullet 1989, the European clinical program effectively stopped.

Thymulin is not FDA-approved. It is not on the FDA 503A bulks list, which means U.S. compounding pharmacies cannot lawfully prepare it. It was not among the 12 peptides FDA removed from Category 2 on April 15, 2026. No commercial pharmaceutical sponsor is advancing it toward an NDA as of June 2026. Current scientific activity is preclinical gene-therapy work centered at the University of La Plata in Argentina.

Thymulin is a distinct molecule from Thymosin Alpha-1 (a separate 28-amino-acid peptide from the Goldstein lab) and from Thymalin (a Russian polypeptide extract developed at the Khavinson Institute of Bioregulation and Gerontology). The three are often confused. They are not interchangeable.

This guide is editorial and educational. It is not medical advice.


H1: Thymulin (FTS / Zinc-Thymulin), A Research-Peptide Guide for 2026

What Is Thymulin?

Thymulin is a nonapeptide (nine amino acids) secreted by thymic epithelial cells, primarily in the thymic medulla. Its serum concentration is a direct biomarker of thymic endocrine function. Levels peak in childhood, decline progressively from adolescence, and approach the limit of detection in old age (Mocchegiani 2006, PMID 16904953).

Sequence and chemistry

The amino acid sequence, established by Pleau and colleagues in 1977 (PMID 914862) from porcine serum, is:

pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn

The N-terminal residue is pyroglutamic acid (pGlu, sometimes written 5-oxoproline), formed by spontaneous cyclization of glutamine. Vendor copy that lists the sequence as “EAKSQGGSN” with a free glutamate N-terminus is describing a non-cyclized variant, not the biologically validated molecule. The pGlu form is the one to verify against any data sheet.

  • Molecular weight, free peptide (apothymulin / FTS, pGlu form): ~857.85 g/mol
  • Molecular weight, zinc-bound active form (1:1 stoichiometry): ~921 g/mol
  • CAS number commonly listed: 63958-90-7

Names and synonyms

Thymulin has acquired several names across five decades of literature, and the inconsistency causes real confusion:

  • Facteur thymique sérique (FTS), the original French name used in the 1970s Bach/Dardenne papers for the apopeptide.
  • Thymulin, the name adopted after the 1982 PNAS zinc paper, used to denote the zinc-bound active form. The INN.
  • Zinc-thymulin / Zn-thymulin / Zn²⁺-FTS, synonyms for the active complex.
  • Nonathymulin, the synthetic chemical equivalent used in the 1980s European clinical trials. PubMed indexes this as a synonym.
  • Thymulin-related peptide (PAT / TRP), a related analog used in the Safieh-Garabedian pain and inflammation work. Not identical to native thymulin.

The Bach lab at Hôpital Necker in Paris isolated FTS in 1977 (Dardenne, J Biol Chem, PMID 303241). Pleau characterized the sequence the same year (PMID 914862). Pleau, Dardenne and Bach published the consolidated chemistry and biology in 1981 (Mol Cell Biochem, PMID 6276717). Dardenne’s 1982 PNAS paper (PMID 6957870) established zinc-dependence and triggered the renaming from FTS to thymulin.

The zinc-dependence is non-negotiable

This is the load-bearing biochemical fact about thymulin and the one most often glossed in marketing copy. The apopeptide (the bare nonapeptide with no metal cofactor) is biologically inert. In binding assays, in T-cell maturation assays, in NK-cell cytotoxicity assays, without zinc, the peptide does nothing reliably reproducible.

Dardenne 1982 (PNAS, PMID 6957870) demonstrated that biological activity requires Zn²⁺ at 1:1 molar stoichiometry. Other divalent cations are either inactive (Mg²⁺, Ca²⁺) or only partially active in some assay systems (Cu²⁺). Laussac et al. 1985 (PMID 3937565) characterized the metal-binding geometry by nuclear magnetic resonance. The central Ser-Gln-Gly-Gly-Ser stretch of the peptide, along with the C-terminal Asn carboxamide, contributes the donor atoms that coordinate the zinc ion.

In vivo, exogenous apothymulin binds endogenous serum Zn²⁺ to assume the active conformation. This is why vendors typically ship the apopeptide and why endogenous zinc status is part of every honest discussion of thymulin biology. It is also why Mocchegiani’s body of work on zinc and immune aging links so tightly to thymulin: when zinc is deficient, the active thymulin pool collapses even if the apopeptide is present.


Mechanism of Action

The mechanism has been characterized in fragments across thirty years of literature. The current best understanding, drawing on Bach/Dardenne 1979 (PMID 231400), Pleau 1981 (PMID 6276717), Dardenne 1982 (PMID 6957870), Dardenne 1993 (PMID 7681212), and the Reggiani 2014 comprehensive review (PMID 24588820):

  1. Synthesis. Thymic epithelial cells in the medulla produce and secrete thymulin into the bloodstream. Schmitt 1980 (PMID 6162253) localized the peptide to thymic epithelial cell cytoplasm by immunoelectron microscopy. Savino 1984 (PMID 6379040) co-localized thymulin-bearing cells with metallothionein, consistent with the zinc-dependence of the secreted molecule.
  2. Zinc binding. Apothymulin binds Zn²⁺ in serum to form the active complex. This step is required before any downstream effect occurs.
  3. Target cells. Zn-thymulin binds specific receptors on T-lineage cells, thymocytes, peripheral CD4+ and CD8+ T cells, and natural killer cells. Gastinel and Pleau (PMID 6304947) characterized the receptor through binding and crosslinking studies. The receptor has not been formally cloned.
  4. Downstream effects.
    – T-cell maturation. Induction of T-cell surface markers in immature thymocytes; differentiation effects on CD3, CD4, and CD8 lineages.
    – IL-2 induction. Enhanced interleukin-2 production by activated T cells.
    – NK cell activity. Dokhelar 1983 (PMID 6195118) showed enhanced NK cytotoxicity in humans after synthetic FTS administration.
    – Cytokine modulation. In animal inflammation models, thymulin reduces IL-1β, TNF-α, and IL-6 (Safieh-Garabedian 2003, PMID 14580936; 2011, PMID 21059360).
    – Analgesia. Animal studies show analgesic effects in inflammatory and neuropathic pain models (Nasseri 2019, PMID 30851702; Safieh-Garabedian 2019, PMID 30503917), mediated in part through α7-nicotinic acetylcholine receptor engagement (PMID 23880090).
  5. Neuroendocrine integration. Endogenous thymulin levels are modulated by growth hormone, prolactin, melatonin, and gonadal steroids. Melatonin acutely raises serum thymulin (Molinero 2000, PMID 10696913). The thymulin-lactotropic axis was characterized in rodents by the La Plata group (Martines 2013, PMID 23941809).

In plain language: thymulin is a small zinc-dependent peptide that nudges T-cell maturation and NK function in the immune system, and that also intersects with the neuroendocrine axis through melatonin and growth hormone. The biochemistry is solid. Whether exogenous administration in humans does anything clinically useful is a separate question, and the answer is in the trials section below.


Preclinical Evidence

The preclinical record is broad and supports thymulin’s identity as a real immunomodulator with measurable effects in animal models. It is also where the recent decade of activity has concentrated, mostly via gene-therapy delivery rather than peptide administration.

Immune restoration in aging models

Aging rodents show declining endogenous thymulin and parallel decline in T-cell function. Mocchegiani’s group at INRCA Ancona built much of the zinc-thymulin-aging axis through observational and supplementation work (Mocchegiani 2006, PMID 16904953). Zinc-replete status partially restores thymulin activity in zinc-deficient aged animals.

Diabetes prevention (alloxan model)

Yamanouchi 1994 (Eur J Pharmacol, PMID 8082705) reported that thymic hormone administration in rats prevented alloxan-induced diabetes. A mechanistic finding rather than a clinical claim.

Ovarian dysgenesis (gene therapy)

Reggiani 2012 (Endocrinology, PMID 22700775) used neonatal thymulin gene therapy in nude female mice and prevented ovarian dysgenesis with attenuation of downstream reproductive derangements. The mechanism is interpreted through a thymus-gonadal axis.

Inflammatory and neuropathic pain (animal)

Multiple Safieh-Garabedian and Nasseri papers (PMIDs 14580936, 21059360, 23880090, 30503917, 30851702) report analgesic and anti-inflammatory effects in rodent pain and central inflammation models. The α7-nAChR mechanism (PMID 23880090) is one of the more mechanistically complete recent threads. None of this work has advanced to a controlled human pain trial.

Allergic asthma (nanoparticle gene therapy)

da Silva 2020 (Sci Adv, PMID 32577505) is the highest-impact recent thymulin paper. It used intratracheal nanoparticles carrying the thymulin gene in a mouse allergic-asthma model and reversed airway eosinophilia, Th2 cytokine elevation, and airway remodeling compared with controls. The work is preclinical and uses gene therapy, not peptide administration.

Adenovector delivery (gene therapy)

Zappa-Villar 2017 (Mol Immunol, PMID 28501652) developed a new adenoviral vector for in-vivo thymulin gene transfer designed for inflammatory-disorder applications. Again, preclinical, gene-therapy.

Veterinary vaccine adjuvant

Barbour 2000 and 2001 (PMIDs 11129855, 11519676) showed that thymulin plus zinc enhanced Salmonella vaccine response in chicken breeders. Mechanistically supportive of an adjuvant role; not translated to human vaccine work.

The preclinical record is consistent with a real anti-inflammatory and T-cell-maturation effect in animals. The translation gap is the human clinical trial record, which is where the story changes.


Human Clinical Evidence

This is the section that decides how thymulin is positioned honestly. There are two blinded human efficacy trials. Both were negative.

Amor 1987, rheumatoid arthritis (the most-cited human efficacy data)

Amor B, Dougados M, Mery C, Dardenne M, Bach JF. Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials. Ann Rheum Dis 1987;46(7):549–554. PMID 3310925.

  • Design: two consecutive double-blind, placebo-controlled trials of nonathymulin (the synthetic thymulin equivalent) in patients with rheumatoid arthritis, evaluated against placebo over multiple months.
  • Route: subcutaneous, parenteral dosing across the microgram-to-low-milligram-per-injection range typical of synthetic thymulin trials of the era.
  • Result: no significant clinical benefit over placebo on standard RA endpoints. Safety profile was favorable with no serious drug-related adverse events. Some immunological parameters shifted, but the shifts did not correlate with clinical outcome.
  • Importance: this is the highest-quality blinded human efficacy data on thymulin or any close analog. The result is negative. Any guide that positions thymulin as a serious rheumatoid-arthritis candidate without addressing Amor 1987 is selectively reading the literature.

Roullet 1989, multiple sclerosis

Roullet E, Cesaro P, Simon-Lavoine N, Degos JD, Marteau R. Nonathymulin treatment of multiple sclerosis: double-blind pilot study. Acta Neurol Scand 1989;80(6):575–578. PMID 2618585.

  • Design: double-blind, placebo-controlled pilot in patients with multiple sclerosis. Small (pilot-scale), parenteral nonathymulin versus placebo across a defined treatment window.
  • Result: no significant clinical benefit over placebo on the MS endpoints evaluated. Safety profile favorable.
  • Importance: the last European blinded efficacy trial of nonathymulin in a major autoimmune indication. The trial is small enough that the result is best read as “underpowered, signal absent.” The field did not pursue a larger MS trial after this.

Together, Amor 1987 and Roullet 1989 are the entire blinded human efficacy record for thymulin. Both negative.

Observational and biomarker studies

The rest of the human literature is observational, biomarker-focused, or zinc-supplementation rather than thymulin-administration. It is real data but it does not establish therapeutic efficacy of exogenous thymulin.

  • Down syndrome with oral zinc. Licastro 1993, 1994 (PMIDs 8019155, 8193451) showed that oral zinc supplementation in children with Down syndrome normalized depressed serum thymulin activity and reduced respiratory infection rates. This is a zinc-supplementation result interpreted through the thymulin-zinc axis. It is not a thymulin-administration trial.
  • Crohn’s disease with zinc. Brignola 1993 (PMID 8364132) showed zinc supplementation restored plasma zinc and thymulin in Crohn’s patients. Again, zinc study, not thymulin administration.
  • AIDS with zinc. Mocchegiani 1995 (PMID 8582783) reported that oral zinc as adjunct to zidovudine reduced opportunistic-infection rates and restored thymulin activity. Mechanistic; not a thymulin trial.
  • Anorexia nervosa. Wade 1985 (PMID 3927699) reported reduced thymulin activity in anorexia patients. Biomarker observation.
  • Cystic fibrosis. Mocchegiani 1995 (PMID 7539347) showed low zinc bioavailability correlated with low thymulin activity and impaired cellular immunity. Biomarker observation.
  • Beta-thalassemia. Consolini 2001 (PMID 11340247) reported altered thymulin and other immune parameters in beta-thalassemia patients. Observational.
  • Nephrotic syndrome in children. Bensman 1984 (PMID 6543358) demonstrated decreased serum thymulin biological activity in pediatric nephrotic syndrome. Biomarker observation.
  • Healthy elderly with zinc-fortified milk. Costarelli 2014 (PMID 24771015) reported a pilot study in very old persons with modest cytokine release and thymic-hormone activity restoration. Pilot, not a thymulin-administration trial.

Honest framing of what is and is not proven

What is proven:

  • Thymulin is a real nonapeptide of thymic-epithelial origin. The sequence is established.
  • Zinc-dependence is established at PNAS-level evidence.
  • Receptor binding and downstream T-cell, NK, and cytokine effects are reproducible.
  • Thymulin levels are a quantitative biomarker of thymic function, zinc status, and age.
  • In the small studied dose range, exogenous nonathymulin appeared safe.

What is not proven:

  • Clinical efficacy of exogenous thymulin in any human indication. The only blinded efficacy trials (Amor 1987 RA, Roullet 1989 MS) were negative.
  • That exogenous thymulin reverses age-related immune decline in humans. The biomarker associations are real; the trial that would establish reversal has never been run.
  • That subcutaneous self-administration at vendor-typical biohacker doses produces clinically meaningful benefit. There is no controlled trial of that protocol.
  • That the synthetic vendor peptide is biochemically equivalent to the validated nonathymulin used in Amor 1987. Pyroglutamate cyclization, zinc-binding form, and stoichiometric purity all matter for biological activity, and vendor quality is uneven.

Dosing

There is no established clinical regimen for thymulin because no regimen has ever been registered or approved anywhere. The dose information below summarizes what the literature reports and what biohacker communities cite. None of it has been validated against a clinical endpoint in a modern trial.

Doses used in published human work

ContextDoseFrequencyRouteDuration
Dokhelar 1983 NK enhancement (PMID 6195118)Microgram-range single doses of synthetic FTSSingle or repeatIV or SCSingle-dose pharmacology
Amor 1987 Phase 2 RA (PMID 3310925)Nonathymulin in microgram-to-low-milligram per injection rangeApproximately weeklySubcutaneousMultiple months
Roullet 1989 MS pilot (PMID 2618585)Nonathymulin at similar order of magnitude as AmorApproximately weeklySubcutaneousPilot duration

Community practice patterns (not validated)

Research-peptide and biohacker communities most commonly cite 50 to 500 mcg per injection, subcutaneous, one to three times per week, with a typical mid-range of around 100 mcg twice weekly (totaling 200 mcg per week). Some protocols use higher doses, into the low-milligram range per week.

Two caveats deserve foregrounding:

  1. Vendor protocols often cite milligram-range doses far above the 1980s clinical trial range. There is no published rationale for these higher doses and no pharmacokinetic data in humans at biohacker-typical doses.
  2. The clinical trials that used trial-validated doses were both negative. Pushing the dose higher than what failed is not a path to a different result without underlying pharmacology to support it.

Pharmacokinetics

  • Plasma half-life: short, minutes to a few hours for the free peptide. The nonapeptide is small and subject to rapid renal clearance and serum proteolysis. No formal published t½ in humans at vendor doses.
  • Bioavailability (SC): assumed near-complete on the timescale of action, though no formal SC PK study is published.
  • Oral bioavailability: effectively zero. The nonapeptide is destroyed by gastrointestinal proteolysis. Do not consider oral thymulin a meaningful route.
  • Carrier protein: Dardenne 1980 (PMID 7189463) identified a serum carrier of FTS that may extend in-vivo activity beyond what the free-peptide PK would predict.

If a calculator preset is needed for educational reference only, 100 mcg subcutaneous twice weekly sits within community practice-pattern range while staying inside the order of magnitude of the 1980s trial dosing. Frame it explicitly as practice-pattern, not validated.


Reconstitution

Thymulin is supplied as a lyophilized white powder, typically in 5 mg vials at research-peptide vendors. Some vendors offer 10 mg vials. Reagent-grade suppliers (BACHEM, Sigma-Aldrich, MedChemExpress, Tocris, Cayman Chemical) sell milligram quantities for in-vitro work at substantially higher per-milligram cost.

Standard reconstitution

  • Diluent. Bacteriostatic water is the standard choice. The benzyl alcohol preservative permits multi-dose use over weeks of refrigerated storage. Sterile water is acceptable for single-use immediately-administered doses.
  • Example dilution (5 mg vial + 2 mL bacteriostatic water): final concentration 2.5 mg/mL = 2,500 mcg/mL. At a 100 mcg dose, draw 0.04 mL, which is 4 units on a U-100 insulin syringe.
  • Alternate dilution (5 mg + 5 mL bacteriostatic water): final concentration 1 mg/mL = 1,000 mcg/mL. At a 100 mcg dose, draw 0.1 mL, which is 10 units on a U-100 insulin syringe.
  • Storage. Refrigerate at 2 to 8 °C after reconstitution. Lyophilized powder stores long-term at -20 °C. Avoid freeze-thaw cycles.

Critical: do not add zinc to the reconstitution vial

Thymulin is a zinc-dependent peptide, and at first reading the instinct may be to add a zinc salt to the reconstitution vial to “activate” the molecule. Do not do this.

Two reasons:

  1. The endogenous zinc pool in serum is what binds the apopeptide in vivo. Vendor product is shipped as the apopeptide. Once injected, circulating Zn²⁺ binds the peptide and produces the active complex. No exogenous addition is needed.
  2. In-vitro complexation at non-physiological pH or concentration can precipitate the peptide. Adding zinc chloride or zinc sulfate to a vial of reconstituted thymulin at the wrong pH risks dropping the peptide out of solution as an insoluble complex or shifting it to non-native geometries that may not match the biologically active form. Vendor and reagent-supplier protocols universally instruct against in-vitro zinc addition.

This is one of the most easily-missed handling errors. If you are reading vendor or community protocols that recommend adding zinc to the vial, treat that as a red flag for the protocol’s overall quality.

Route

Subcutaneous is the canonical and most-studied route. Intramuscular is acceptable. Do not consider these other routes:

  • Oral. Not bioavailable.
  • Intranasal. No clinical data. The molecular weight and physical chemistry make mucosal absorption uncertain.
  • Transdermal. Not feasible for a 9-amino-acid peptide.

Standard subcutaneous injection technique: rotate sites (abdomen, thigh, deltoid), use a 27 to 31 gauge insulin syringe, and follow basic aseptic technique.


Safety

In the small published human program of the 1980s European trials plus the broader observational and zinc-supplementation literature, thymulin has not been associated with serious adverse events. The trials that exist failed for efficacy reasons, not safety reasons.

Adverse events reported

Adverse eventPatternSource
Injection-site reactionsMild, transient erythema or pruritus; self-resolvingAmor 1987, community reports
Mild fatigue or flu-like sensationReported anecdotally; not statistically separable from placeboAmor 1987
HeadacheLow frequency, similar to placeboAmor 1987, Roullet 1989
Serious adverse eventsNone attributed to drug in the published human programAmor 1987, Roullet 1989

Why the safety profile is benign

  • The peptide is small, endogenously present in human serum across the lifespan, and exogenous administration is replacing or augmenting an endogenous molecule.
  • Zinc-dependence self-limits biological activity by endogenous zinc availability.
  • Renal clearance is fast (short t½). No accumulation risk on weekly dosing.

Contraindications and cautions

  • Known hypersensitivity to thymulin or excipients.
  • Active autoimmune disease. Theoretical caution. Thymulin is immunomodulatory and was tested in autoimmune indications (rheumatoid arthritis, multiple sclerosis) without efficacy and also without observed flare, but the absence of harm in those trials is not equivalent to documented safety in active disease.
  • Active malignancy. Theoretical caution. Immunomodulators carry theoretical risk in active hematologic malignancy. No data.
  • Pregnancy and lactation. No data. Conservative editorial stance is to avoid.

Safety at vendor-typical biohacker doses

The safety record is for the dose range studied in the 1980s trials. Vendor community protocols sometimes use doses substantially higher than what was studied. Safety at those higher doses is unstudied. The published safety profile does not extend to dose ranges the trials did not test.


Drug Interactions

In the absence of formal pharmacokinetic or pharmacodynamic interaction studies in humans, the interaction landscape is theoretical. The major considerations:

  • Zinc supplementation. Mechanistically synergistic. Mocchegiani’s body of work supports zinc-replete status as a prerequisite for endogenous thymulin to function. No formal “exogenous thymulin plus zinc supplementation” dose-finding trial has been run. The co-administration is biologically rational; the optimal stoichiometry in humans is not established.
  • Melatonin. Physiological co-regulator. Molinero 2000 (PMID 10696913) established that melatonin acutely raises endogenous thymulin in rats and humans. Co-administration is not contraindicated but is unstudied.
  • Growth hormone, GHRH, GH secretagogues (sermorelin, CJC-1295, ipamorelin, tesamorelin). The thymulin and growth hormone axes are interrelated. Meazza 2007 (PMID 17447187) characterized the relationship in neonates. No formal human interaction study exists.
  • Immunosuppressants (corticosteroids, methotrexate, biologics). Theoretical antagonism. Corticosteroids suppress thymulin production. Co-administration is not contraindicated but the net effect on outcome is unstudied.
  • Other thymic peptides (Thymosin Alpha-1, Thymalin). Community protocols sometimes stack these. The mechanisms overlap but the molecules are distinct. No controlled stack data exists.
  • Vaccines. Veterinary work (Barbour 2000, 2001; PMIDs 11129855, 11519676) suggests thymulin plus zinc enhanced vaccine response in chickens. No published human vaccine adjuvant trial.

Regulatory Status (June 2026)

  • FDA approval: None. Thymulin does not appear in Drugs@FDA, has no Orange Book entry, and has no approved indication anywhere in the world.
  • FDA 503A bulks list: Not listed. Thymulin is not a Category 1 bulk drug substance under 21 CFR 216.23. It has no USP monograph and is not a component of any FDA-approved drug. It therefore cannot lawfully be compounded by a 503A pharmacy in the United States.
  • FDA April 15, 2026 framework: Thymulin was not among the 12 previously-restricted peptides FDA removed from Category 2 on April 15, 2026. It remains in the broader “research peptide, no compounding pathway” bucket.
  • DEA scheduling: Not scheduled. Not a controlled substance.
  • Orphan-drug designation: None on record.
  • EMA marketing authorization: None. The 1980s nonathymulin trials in France and Italy were investigator-initiated and never advanced to a marketing authorization application.
  • Active commercial sponsor: None as of June 2026. The principal active academic program is the Goya and Reggiani group at the University of La Plata in Argentina, working on gene-therapy delivery in rodent models.
  • Active recruiting Phase 1/2/3 trial: None that we can identify in major registries as of June 2026.

The standing editorial framing: thymulin is a research peptide. Any U.S.-facing vendor sale is under “research use only” terms. Consumer self-administration is outside any regulated supply chain. The 1980s European blinded trials provide the only human efficacy data, and both were negative.

How thymulin differs from Thymosin Alpha-1 and Thymalin

These three thymic peptides are conflated constantly in vendor copy. They are distinct molecules.

  • Thymosin Alpha-1 (Tα1, Zadaxin). 28-amino-acid peptide. Goldstein lab origin (Allan Goldstein, George Washington University). Approved in over 30 countries outside the United States for hepatitis B, hepatitis C, and as an adjunctive cancer therapy. Held under FDA IND in the U.S. Different sequence, different program, different regulatory status.
  • Thymalin (тималин). Russian polypeptide extract from calf thymus. Not a single defined peptide, a low-molecular-weight peptide fraction. Developed by V.G. Morozov and V.Kh. Khavinson at the Institute of Bioregulation and Gerontology in St. Petersburg. Used clinically in Russia for immunomodulatory indications. Mechanism overlaps with thymulin and the Khavinson peptide bioregulators but is biochemically distinct.
  • Thymopentin (TP-5). A different pentapeptide (Arg-Lys-Asp-Val-Tyr) representing an active fragment of thymopoietin. Separate molecule, separate program, marketed historically in Europe under names including Timunox.

The three are not interchangeable. Thymulin is the 9-amino-acid zinc-dependent nonapeptide. Read the specific guide for each.


  • Thymosin Alpha-1: The 28-amino-acid thymic peptide with FDA IND status in the United States and approval in over 30 countries elsewhere. The peptide most commonly confused with thymulin.
  • Thymalin: The Khavinson Institute’s polypeptide thymus extract. Russian clinical-research pedigree. Distinct from thymulin and from Thymosin Alpha-1.
  • Tuftsin: A tetrapeptide immunomodulator (Thr-Lys-Pro-Arg) historically derived from the Fc region of IgG. A separate immune-modulating peptide with its own (also limited) clinical record.
  • Splenopentin: A pentapeptide (Arg-Lys-Glu-Val-Tyr) representing an active fragment of splenin, sometimes discussed alongside thymopentin and thymulin in the broader “small peptide immunomodulator” family.

Disclaimer

This guide is editorial and educational. Thymulin is a research peptide that is not FDA-approved, not on the FDA 503A bulks list, and not legally compoundable by U.S. pharmacies. The two blinded human efficacy trials (Amor 1987 in rheumatoid arthritis, Roullet 1989 in multiple sclerosis) were both negative. Nothing in this guide is medical advice. Consult a qualified clinician before considering any peptide intervention.

Get peptide updates

Monthly peptide updates and FDA alerts. No spam, unsubscribe anytime.

Cycle Lengths

Cycling summary: No established cycling protocol for this peptide in the published literature. Community protocols vary; consult a compounding-focused clinician for a personalized plan.

Cycle timing should be informed by the peptide’s half-life, receptor tachyphylaxis profile (if applicable), and personal response monitored through lab work. Log both on-cycle and off-cycle biomarkers to understand recovery kinetics.

Lab Monitoring

Thymulin is a research-tier healing peptide with no established peripheral efficacy biomarker. Lab monitoring should be prudent general-health surveillance rather than efficacy tracking. The panels below cover organ systems most relevant during peptide research use.

Baseline (before starting): CBC with differential, comprehensive metabolic panel (CMP) covering LFTs and renal function, fasting lipid panel, hs-CRP for inflammatory baseline, fasting glucose, and HbA1c if metabolic risk factors are present. Age-appropriate cancer screening is prudent given rodent-only data on healing/angiogenic activity for most research peptides in this class.

During use: repeat CMP + CBC every 8-12 weeks. Repeat hs-CRP alongside if using for inflammatory conditions to track the inflammatory read against symptom response. Watch trends in ALT/AST (liver) and eGFR (renal) rather than single readings.

What to flag to a physician: injection-site erythema or nodule formation, unexplained weight changes, new joint or mass symptoms, any lab value trending outside reference range across two consecutive draws.

For the full class-wide monitoring framework and a plain-language comparison of DTC lab services for peptide users, see the Peptide Lab Testing pillar guide.

Storage & Travel

Storage

Lyophilized powder: Lyophilized powder freezer -20°C (-4°F) for long-term storage; stable at room temperature for shipping and short-term handling.

Reconstituted: Refrigerate reconstituted vial at 2-8°C (36-46°F); use within ~28 days per USP <797> peptide stability guidance. Never freeze a reconstituted vial, since freeze-thaw cycles damage peptide bonds and reduce potency.

Travel

Domestic flights: pack reconstituted vials in an insulated cooler with reusable ice packs. The TSA 3-1-1 rule limits liquids to 100 mL per container in carry-on; a 3-5 mL peptide vial passes with room to spare. Keep pharmacy or vendor documentation visible for TSA questions. Lyophilized powder in original sealed vial does not require cooling for short trips.

International travel: Thymulin is a research peptide in most jurisdictions with varying import restrictions — check the destination country’s rules before travel. Carry a physician’s letter if the peptide was prescribed by a compounding-focused clinician.

Road trips: keep the cooler in the cabin, not the trunk, during summer. Hotel mini-fridges vary in temperature stability; an insulated bag inside the mini-fridge adds a buffer.

Emergency out-of-fridge: reconstituted Thymulin at room temperature under 24 hours is generally still viable per USP stability guidance. Longer excursions or temperatures above 30°C compromise potency; discard and reconstitute a fresh vial.

Similar Posts